Fig. 9From: A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cellsGrowth inhibition by EG22 and ZSM02 in a cell panel with varied levels of MGMT. They show similar growth inhibition profile with an increased potency when compared to temozolomide (TMZ), ANI and ANI + TMZ, indicating that their potency is independent of the MGMT status of the cellsBack to article page